Prof. Dr. med. Peter Fasching

Department of Obstetrics and Gynaecology Professur für Translationale Frauenheilkunde und Geburtshilfe

DETECT V/CHEVENDO - duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom (2020) Friedl TWP, Polasik A, Tzschaschel M, Schochter F, De Gregorio A, Fasching P, Taran FA, et al. Conference contribution Documentation Behavior in the CANKADO eHealth-Application and Effects on observed Side Effects - An exploratory Analysis of the PreCycle-Study (2020) Schmidt M, Degenhardt T, Fasching P, Wurstlein R, Lueftner D, Kates RE, Schumacher J, et al. Conference contribution Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer. (2020) Pavanello M, Dicks E, Song H, Ariff A, Bolithon A, Intermaggio MP, Pinese M, et al. Conference contribution Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) Liu J, Prager-van der Smissen WJ, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, et al. Journal article Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α (2020) Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching P, Hoskin TL, Singh RJ, et al. Journal article ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 (2020) Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching P, Augustin D, Briest S, et al. Journal article, Review article Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials (2020) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Journal article Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution